Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Abstract

Combined intravitreal ranibizumab and PDT was significantly more effective in maintaining and improving VA for PCV patients compared with PDT monotherapy over 24 months.

One-Year Outcomes Comparing Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation

“…Administered therapies appear to be more effective in treatment-naive cases 18 and cases with stage II lesions; both observed decrease in recurrences (16,20). In addition to the anatomically successful outcomes with anti-VEGF monotherapy noted by Arias et al (16) and in the present study, there are also findings indicating that PDT combined with anti-VEGF, triamcinolone, and other modalities were superior to anti-VEGF monotherapy (17)(18)(19).…”

“…This result differs from the results reported by Arias et al and the present study, but both of those studies included patients who had previously received AMD treatment, unlike the study of Rouvas et al, which enrolled treatment-naive patients. In a case report review presented by Saito et al, (18) increase was reported in the combined treatment group. Nakano et al (19) reported similar results to Rouvas et al, indicating a better increase in BCVA and decrease in CMT for PDT combined with subtenon triamcinolone than PDT monotherapy and combined PDT+anti-VEGF.…”

“…As demonstrated by studies in literature, anti-VEGF treatment either as a monotherapy or in combination with PDT, has proved to be an efficient method of preserving visual acuity and providing anatomical success (10)(11)(12)(13)(14)(16)(17)(18)(19). Our study also presented results with preserved visual acuity and improved macular anatomy.…”

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

“…PDT combined with anti-VEGF therapy is currently recommended for treatment of PCV and was reported to have good visual outcome in patients suffering from PCV. [22][23][24][25] However, relatively few studies have investigated the visual prognostic factors following PCV treatments, [26][27][28][29][30] especially the predictive factors following combined therapy. Some of the clinical factors such as age, baseline best-corrected visual acuity and size of haemorrhage, and presence of PED were reported to govern the final visual outcome.…”

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population

“…Combination anti-VEGF and photodynamic therapy (PDT) has been evaluated in both Asian [15][16][17][18][19] and White 20 patients with PCV, with no clear consensus on the superiority of PDT or combination therapy. Most of these studies were conducted in predominantly Asian populations.…”